Galantamine 5 mg/ml: An Injectable Cholinergic Enhancer for Cognitive and Neuromuscular Support

When neurons lose the capacity to efficiently exchange signals — whether due to neurodegenerative dementia, stroke sequelae, or impaired neuromuscular transmission — memory, thinking, and the capacity to move all suffer. Galantamine 5 mg/ml in ampoules is an injectable formulation of an alkaloid first isolated from the Caucasian snowdrop (Galanthus woronowii) that amplifies cholinergic transmission throughout the central and peripheral nervous systems. The 10-ampoule pack is intended for course-based parenteral administration in a hospital setting or under strict outpatient medical supervision.

🧠 Biochemical Mechanism: A Dual Strike Against Cholinergic Deficiency

Galantamine targets the acetylcholine system from two angles simultaneously, distinguishing it favorably from many other cholinergic agents:

1. Reversible Inhibition of Acetylcholinesterase.

Acetylcholine is the neurotransmitter responsible for signal transmission at synapses critically involved in memory and learning (particularly within the hippocampus and cerebral cortex), as well as at neuromuscular junctions. The enzyme acetylcholinesterase rapidly degrades acetylcholine within the synaptic cleft, terminating the signal. Galantamine reversibly binds to the active site of this enzyme, extending the lifespan of acetylcholine within the synapse and potentiating cholinergic transmission.

2. Allosteric Modulation of Nicotinic Receptors.

Unlike most cholinesterase inhibitors (donepezil, rivastigmine), galantamine also binds to an allosteric site on nicotinic acetylcholine receptors. This heightens their sensitivity to acetylcholine and enhances the presynaptic release of the neurotransmitter. The result is not only a quantitative increase in synaptic acetylcholine but also a qualitative improvement in its reception by the postsynaptic membrane.

This dual mechanism achieves:

• Enhancement of cognitive functions (memory, attention, processing speed).
• A slowing of the symptomatic progression of dementia.
• Facilitation of neuromuscular transmission in pathologies of the peripheral nerves and synapses.

📋 Clinical Indications

Galantamine in injectable form is deployed in the following clinical scenarios:

1. Alzheimer's Disease and Other Dementias:

• Mild to moderate Alzheimer's-type dementia. Galantamine ranks among the first-line agents for symptomatic therapy, offering temporary improvement in cognitive performance and daily living activities.
• Vascular dementia and mixed forms.

2. Sequelae of Cerebrovascular Events:

• The recovery phase following ischemic stroke. Galantamine may aid in the rehabilitation of cognitive functions impaired by a cerebrovascular catastrophe.

3. Peripheral Nervous System Disorders:

• Polyneuropathies of diverse origin (diabetic, toxic, alcoholic) presenting with paresis and sensory disturbances.
• Mononeuropathies (e.g., facial nerve neuropathy).

4. Neuromuscular Transmission Disorders:

• Myasthenia gravis and myasthenic syndromes (as part of combination therapy).
• Residual neuromuscular blockade following the use of non-depolarizing muscle relaxants (in anesthetic practice).

5. Poliomyelitis and Post-Polio Syndrome (as a component of rehabilitation programs).

💉 Administration and Dosing Regimen

Galantamine in ampoules is designated for parenteral administration:

• Routes of Administration: Subcutaneous, intramuscular, or intravenous. The specific route and infusion rate are determined by the treating physician.
• Dosing: Titrated on an individual basis. Therapy commences at minimal doses, with gradual escalation to the optimum therapeutic level.
  • Adults: The starting dose is typically 2.5–5 mg per day. Subsequently, if well tolerated, the dose may be increased to 10–20 mg/day, divided into two administrations.
  • Adjustment in Hepatic and Renal Impairment: Dose reduction may be warranted in patients with moderately compromised liver or kidney function.
• Course Duration: Generally spans 4 to 12 weeks. The decision to extend therapy is made by the physician based on the trajectory of clinical symptoms and drug tolerability.

⚠️ Contraindications

Galantamine must not be prescribed in the following conditions:

• Hypersensitivity to galantamine or any component of the solution.
• Severe Hepatic Impairment (Child-Pugh Class C).
• Severe Renal Impairment (creatinine clearance below 9 ml/min).
• Severe Bronchial Asthma, Chronic Obstructive Pulmonary Disease in the acute exacerbation phase.
• Bradycardia (heart rate below 50 beats per minute), sick sinus syndrome, high-grade atrioventricular block.
• Active Gastric and Duodenal Ulcer Disease.
• Epilepsy (galantamine may lower the seizure threshold).
• Mechanical Intestinal or Urinary Tract Obstruction.
• Pregnancy and Lactation.
• Children Under 9 Years of Age.

📊 Safety Profile and Adverse Reactions

The undesirable effects of galantamine are generally linked to its cholinergic action and are most pronounced during the dose-titration phase:

• Gastrointestinal Tract: Nausea, vomiting, diarrhea, abdominal pain, decreased appetite, dyspepsia.
• Cardiovascular System: Bradycardia, orthostatic hypotension, less commonly — hypertension.
• Central Nervous System: Dizziness, headache, somnolence, insomnia, confusion, tremor.
• Other: Increased sweating, hypersalivation, muscle cramps, weight loss, allergic reactions.

To minimize gastrointestinal side effects, adequate food and fluid intake is recommended. Should pronounced bradycardia or syncopal episodes develop, immediate medical evaluation is mandatory.

📦 Storage Conditions

Ampoules must be kept in the original packaging, protected from light, at a temperature of 15–25 °C (59–77 °F). Keep out of the reach of children. Do not freeze.

📦Find out about the delivery to your country on WhatsApp